George Simeon
George Simeon is CEO at Curevo Vaccine. He founded Curevo Vaccine, which was acquired by Eli Lilly. His expertise includes vaccines, biotech, and corporate strategy.
Recent coverage
Front-page news, podcasts and videos about George
Curevo Raises $110M Series B to Advance Shingles Vaccine Amid GSK Competition, Adds Former GSK and Moderna Execs to Board
Seattle biotech startup Curevo raised $110 million in a Series B round to advance Phase 2 trials of its shingles vaccine amezosvatein, competing with GlaxoSmithKline's Shingrix. The company added biotech veterans, including former GSK and Moderna executives, to its board to support development.
Curevo raises $60M to test shingles vaccine vs. GSK’s $2.3B-a-year Shingrix in 650+ person phase 2b trial
Seattle vaccine startup Curevo raised $60 million to fund a phase 2b trial comparing its shingles vaccine against GSK’s market-leading Shingrix, aiming to reduce side effects while preserving strong immune responses. The shot uses a non-living viral component plus a proprietary adjuvant and was developed through a 2018 partnership including GC Pharma, the Mogam Institute, and Seattle’s IDRI.
Organizations
See all 10-
Curevo Vaccine CEO · current
-
Curevo Executive Officer, Director 2022–2019, Former Chairman & Chief Executive Officer 2019 · past
-
Black Kactus LLC CEO 2018–2020 · past
Education
-
Università Bocconi Master of Philosophy - MPhil, Strategy & Technology Management · 2004–2007
-
INSEAD MBA · 1998–1999
-
Yale School of Public Health Master of Public Health - MPH, Epidemiology, Health Economics · 1992–1994
-
University of Ottawa B.Soc.Sc, Economics · 1988–1992
